-+ 0.00%
-+ 0.00%
-+ 0.00%

COCRYSTAL PHARMA’S INVESTIGATIONAL DRUG CANDIDATE CC-42344 DEMONSTRATES STRONG ANTIVIRAL POTENCY AGAINST THE 2024 HIGHLY PATHOGENIC H5N1 AVIAN INFLUENZA STRAIN

Reuters·05/29/2025 12:01:02

Please log in to view news